OnCo
peoplePerson

Tanios Bekaii-Saab

GI oncologist behind trials of KRAS, HER2, and FGFR-directed therapy in colorectal and bile duct cancer.

Medical oncologist leading gastrointestinal cancer research at Mayo Clinic in Arizona. Investigator on ANCHOR CRC and MOUNTAINEER, and on FGFR2 inhibitor trials in cholangiocarcinoma; a frequent voice on colorectal cancer treatment sequencing.

Role
Professor of Medicine; Leader, GI Cancer Program, Mayo Clinic Arizona
Institution
Mayo Clinic
Specialisms
Gastrointestinal oncologyColorectal cancerBiliary cancer

Papers

2top
TitleJournalYear
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12CNew England Journal of Medicine2023
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 studyLancet Oncology2019

Key papers

1top
rctThe Lancet 2023changed practice
NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer

For fit patients with newly diagnosed metastatic pancreatic cancer, a FOLFIRINOX-type regimen is now proven to be better than gemcitabine plus nab-paclitaxel, settling a long-standing debate. The absolute gain is about two months of median survival, and the regimen is more toxic for the gut. Whether liposomal irinotecan adds anything over conventional irinotecan (standard FOLFIRINOX) has never been tested head-to-head.

Connected

10top

cancers

3
Biliary tract cancer (cholangiocarcinoma)Colorectal cancerPancreatic ductal adenocarcinoma

targets

3
FGFR2HER2KRAS

institutions

2
Mayo ClinicMayo Clinic Comprehensive Cancer Center – Arizona

trials

1
MOUNTAINEER & MOUNTAINEER-03

key papers

1
NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer